The Vector State Research Center of Virology and Biotechnology based in the Koltsovo academic town in the Novosibirsk region will submit at least one type of Ebola vaccine for clinical tests in August, Vector General Director Valery Mikheyev told reporters on the sidelines of the Technoprom 2015 forum on June 4.
"We have several kinds [of the vaccine] and we will submit them for clinical tests shortly. One of our formulas is ready [to be tested] and another two or three will be ready soon," Mikheyev said.
The Russian government has given the order to begin the clinical tests in August, he added.
According to the general director, Vector is about to start the production of dry nutrient media for virology research and medicinal substances.
"We are in the process of registration of Ridostin, which is undergoing the second phase of clinical trials. It is an immunomodulator, and we are testing it with acute respiratory infections and flu," he said.
Also, Vector will this year begin the production of Neitrostim, a medicine helping people recover from x-ray therapy.
All rights reserved by Rossiyskaya Gazeta.